Targeting skeletal muscle AMP-activated protein kinase to treat type 2 diabetes.
Taylor
Eric B
EB
The Joslin Diabetes Center and Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA. laurie.goodyear@joslin.harvard.edu
Goodyear
Laurie J
LJ
D055372:AMP-Activated Protein Kinases; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology*; D004789:Enzyme Activation / Q000187:drug effects; D020536:Enzyme Activators / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D009097:Multienzyme Complexes / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D021122:Protein Subunits / Q000378:metabolism; D012265:Ribonucleotides / Q000494:pharmacology / Q000627:therapeutic use
D020536:Enzyme Activators; D007004:Hypoglycemic Agents; D009097:Multienzyme Complexes; D021122:Protein Subunits; D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide